CohBar's Acquisition Partner Touts Encouraging Data From Personalized Cancer Vaccine

Morphogenesis Inc and CohBar Inc CWBR announced initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol-directed IFx-Hu2.0 therapy for Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) patients who exhibited primary resistance to ICIs.
Related: CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
IFx-Hu2.0 is Morphogenesis' lead personalized cancer vaccine candidate designed to overcome primary resistance to checkpoint inhibitors.
The ongoing Phase 1b study evaluates IFx-Hu2.0 in a two-stage study design to assess the safety and to examine the effects of repeated weekly dosing for up to 3 weeks on the magnitude of the ensuing systemic immune response to determine the optimal dose and schedule for a planned Phase 2/3 registration directed trial.
Four of 5 (80%) patients with advanced MCC and 1 of 2 (50%) patients with cSCC, or 5 of 7 total (71%), experienced objective anti-tumor responses to ICI rechallenge in this setting, with a duration of response ongoing in 4 patients and one response lasting 23 months.
Based on the positive preliminary results, an additional 11 patients are planned for enrollment in the expansion stage of the Phase 1b study using the weekly x 3 dosing schedule.
Additional exploratory/biomarker analyses are planned.
Price Action: CWBR shares are down 1.37% at $2.77 on the last check Monday.